Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five weeks after re-induction treatment and nine days after discharge from hospital, remittent fever occurred in a 34-year-old woman with promyelocytic leukaemia in full remission. She also had haemolytic anaemia and thrombocytopenia, as well as a reduced creatinine clearance. Findings on physical examination were unremarkable, but Falciparum malaria was found in the blood smear. Infusion of erythrocyte or platelet concentrates, administered in treating the leukaemia, was the probable source of the infection. Ten days after starting the administration of chloroquine and sulfadoxine-pyrimethamine she was discharged from hospital, cured of the malaria.
 ...
PMID:[Transfusion malaria in promyelocytic leukemia]. 305 88

cis-Diamminedichloroplatinum (cis-platinum) is an effective and widely used antitumor drug. Patients receiving cis-platinum, however, experience very profound and long lasting gastrointestinal symptoms. The role of intestinal mucosal toxicity in the pathogenesis of these symptoms is unclear. In this study we have investigated the thiol-containing compound mesna (sodium-2-mercaptoethanesulfonate) as a potential antidote to cis-platinum-induced gastrointestinal tract damage. In mice, mesna caused a significant reduction in the gastrointestinal toxicity of cis-platinum assessed by electron microscopy, villus recovery rate, and by disaccharidase estimations. Mesna also significantly reduced serum creatinine levels following cis-platinum. Administration of mesna prior (or immediately following) a 67% lethal dose of cis-platinum protected 87-100% of the animals from the lethal effects. The antitumor efficacy of cis-platinum in L1210 leukemia bearing mice was not affected by coadministration of mesna indicating that the protective effect may be tissue specific. In addition this finding indicates that mesna has potential as an agent which may improve the therapeutic index of cis-platinum in clinical practice.
 ...
PMID:Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum. 308 25

The study investigates clinical nutrition of oncological patients as an essential adjuvant component in the whole therapeutical concept. The main subject of the study was the transfer of nutritional concepts which were developed in non-malignant diseases to oncological patients. We defined the homeostasis of patients by biochemical and biophysical parameters in blood (osmolality, Na, K, total protein, albumin, triglycerides, NEFA, glucose, lactate, creatinine, urea, total nitrogen, amino acids) and urine (volume, osmolality, Na, K, creatinine, urea, total nitrogen, and amino acids). Of special interest was the homeostasis of nitrogen, which was characterized by the loss of nitrogen and nitrogen balances. 10 patients with either transplantable panmyeolopathy or leukemia were investigated including a phase of immunsupressive treatment by total body radiation and cytostatic treatment. Parenteral nutrition was made with amino acids (1 g/kg/d), carbohydrates (6.5 g/kg/d) and fat (1 g/kg/d). During the preparatory phase nutrition was interrupted for two consecutive days because high amounts of electrolyte solution with up to 6 1/day were needed to protect the kidney. The period of investigation covered the complete period of treatment which endured up to three months. The essential result was the achievement of a constant body weight which decreased drastically under the conventional treatment without optimized nutrition. The homeostasis remained unchanged inspite of the fact that great changes occurred individually. Nitrogen balance and nitrogen loss demonstrate the strong influence of immun-suppresive treatment with N-losses of up to 20 g per day.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Adjuvant parenteral nutrition in chemo- and radiotherapeutic measures in hematology]. 309

A monoclonal antibody specific for a modified nucleoside, 1-methyladenosine, was prepared and characterized. This antibody, termed AMA-2, reacts with 1-methyladenosine and 1-methyladenine but not with other nucleosides, particularly methylated adenosines other than 1-methyladenosine and methylated guanosines, tested in this investigation. In our experiments, AMA-2 was used in an enzyme-linked immunosorbent assay (ELISA) system for the quantitation of the levels of 1-methyladenosine in urine. Sensitivity was in the picomole range and accuracy was nearly equal to that of the high-performance liquid chromatography (HPLC) assay system. Urinary levels of 1-methyladenosine in healthy donors and patients with various advanced cancers were determined by the inhibition ELISA. The amount of 1-methyladenosine in urine of 33 healthy donors was 1.91 +/- 0.66 nmol/mumol creatinine. In 54% (51/94) of patients, urinary 1-methyladenosine was elevated above the mean plus 2 standard deviations for the healthy donors (3.23 nmol/mumol creatinine). In patients with leukemia, esophageal cancer, stomach cancer, colon cancer, and bladder cancer, urinary levels of 1-methyladenosine were significantly elevated. In patients with leukemia, urinary 1-methyladenosine levels changed almost in parallel with the change in the clinical response during chemotherapy. These results suggest that urinary 1-methyladenosine might be useful in monitoring the effectiveness of therapy.
 ...
PMID:Preparation of a monoclonal antibody specific for 1-methyladenosine and its application for the detection of elevated levels of 1-methyladenosine in urines from cancer patients. 314 1

A discriminant function that predicts whether a patient will require more than one intervention by the pharmacokinetic consultation service (PCS) was derived and evaluated prospectively. In phase 1, peak and trough serum aminoglycoside concentrations were evaluated for each of the 150 patients. The patients were then classified into either group 1 or group 2. Group 1 patients required a change in regimen after the initial recommended regimen was begun, while patients in group 2 did not require a change in regimen. Forty-seven variables of group 1 and group 2 were compared by univariate analysis. Stepwise discriminant analysis was then used to develop a model for classifying patients into either group 1 or group 2. In phase 2, the discriminant function derived in phase 1 was applied to a new group of 47 patients. In phase 1, significant variables of the derived discriminant function, in decreasing order of significance, were leukemia, serum creatinine concentration, location in an intensive-care unit (ICU), male sex, actual volume of distribution, therapeutic trough concentration, and number of days in the ICU before consultation. In phase 2, 6 (23%) of the 26 patients who actually required a change were classified into group 2, and 8 (38%) of the 21 patients who were assigned to group 1 for continuous monitoring did not actually require a regimen change. Although the results of the derived discriminant function were significant, the function's clinical utility in predicting the need for a second dosing intervention was poor.
 ...
PMID:Predicting need for pharmacokinetic consultation follow-up using discriminant analysis. 324 Jun 60

Determinations of methylamine and dimethylamine in the fecal samples from normal subjects (n = 22), nonhemodialysis patients (n = 10), and hemodialysis patients (n = 14) with chronic renal failure have been made by high-performance liquid chromatography of their 2,4-dinitrophenyl derivatives. Fecal methylamine level was significantly lower in the normal group than in the nonhemodialysis group (P less than 0.05) and in the hemodialysis group (P less than 0.05). The mean dimethylamine value of the hemodialysis group was significantly higher than that of the nonhemodialysis group (P less than 0.01) and that of the normal group (P less than 0.005). The method has also been applied to the determination of the two amines in the fecal samples from two patients with leukemia who had been isolated and sterilized in the laminar air flow rooms. Preliminary in vitro experiments were given of the possible pathway for the production of these amines by the incubation of normal fecal samples with added creatinine.
 ...
PMID:Fecal methylamine and dimethylamine in chronic renal failure. 324 71

Proton NMR longitudinal relaxation times (T1; 10.7 MHz; 37 degrees C) were measured in the kidneys and blood serum of mice inoculated with P388 leukemia, and/or treated with the chemotherapeutic drug cis-diamminedichloroplatinum(II) (cis-Pt). In parallel, serum total protein content, urea and creatinine levels were determined and protein fractions were separated electrophoretically. Serum T1 was found to be 1518 +/- 73 ms (1 SD) in control mice, 1670 +/- 69 ms in leukemic mice, and 1380 +/- 71 ms in the healthy and the leukemic cis-Pt treated mice. The T1 increase in leukemic serum and T1 decrease in the serum of cis-Pt injected mice are attributed to decreased and increased protein contents respectively. A detailed analysis in terms of electrophoretic fractions of serum proteins reveals that the serum relaxation rate 1/T1 is a multilinear function of the mass concentrations of the main serum protein fractions, explaining all serum T1 effects. This makes T1 a non-specific blood parameter. The kidney T1 was found to be 311 +/- 12 ms in normal mice and 334 +/- 20 ms in leukemic mice. A dramatic T1 increase is observed when the mice are injected with cis-Pt; the values are 400 +/- 38 ms and 407 +/- 39 ms for healthy and leukemic mice, respectively. This effect is related to the nephrotoxicity of the drug, as evidenced by serum urea and creatinine levels and protein content being higher than normal.
 ...
PMID:The relationship between serum water proton T1 and protein content in the P388 leukemic mouse and the effect of chemotherapy by cis-diamminedichloroplatinum(II). 327 29

Branched chain amino acids (BCAA) improve nitrogen balance and end-organ function in surgical patients, but are untested in marrow transplant recipients. We compared nitrogen balance, urinary 3-methylhistidine-to-creatinine ratio, upper arm anthropometry, serum prealbumin, and day to peripheral engraftment in a randomized, double-blinded trial between 45% (high-leucine) and 23% BCAA intravenous solutions in 40 adult leukemia patients for 1 month following allogeneic marrow transplantation. Nutritional support, provided at approximately 30 nonprotein calories/kg and 0.21 g nitrogen/kg ideal weight, did not differ between groups. Despite greater nitrogen loss and muscle breakdown evidenced by increased 3-methylhistidine-to-creatinine ratio and loss of arm muscle area by study end in the 45% BCAA, no statistical differences were observed when nitrogen balance was compared by week and within stress level as defined by organ and infectious complications. It is likely the patients in the 45% BCAA experienced greater metabolic stress by study end. Serum prealbumin and day posttransplant to peripheral engraftment also did not differ between groups. The chances (power) of this study exceeded 85% in detecting a difference in nitrogen balance of 2.5 g during study week 1 and 4.0 g during week 2. The power during week 3 was 77% for detecting a difference of 4.0 g, and it is unlikely that the true difference exceeds this magnitude. Thus, we did not find any evidence that intravenous BCAA-enriched solutions improved nitrogen balance during the first month after marrow transplantation.
 ...
PMID:Intravenous branched chain amino acid trial in marrow transplant recipients. 329 17

To determine the effect of anti-neoplastic chemotherapy on the vascular system(s) of children with leukemia/lymphoma, urinary excretion of 6-keto-PGF1 alpha was measured by radioimmunoassay (RIA). In 4 patients receiving therapy, 6-keto-PGF1 alpha increased to a mean of 148 (range; 126-170)% during therapy, then returned to pre-treatment level 3-5 days later. In 18 long-term survivors who had completed therapy, 6-keto-PGF1 alpha was determined to be a mean of 275 (range; 52-905) ng/g creatinine, and in the healthy control children the mean was 146 (range; 71-348) ng/g creatinine. These results were contrary to our hypothesis that chemotherapy might cause a decreased synthesis of PGI2, a precursor of 6-keto-PGF1 alpha, and suggest that increased urinary 6-keto-PGF1 alpha reflects a vascular response to acute exposure to chemotherapeutic drugs and possible vascular damage due to long-term intensive chemotherapy in pediatric patients with leukemia/lymphoma.
 ...
PMID:Urinary 6-keto-PGF1 alpha level in patients with childhood leukemia/lymphoma; a possible indicator of vascular damage. 347 70

Twelve evaluable patients with progressive hairy cell leukemia were treated with deoxycoformycin at a dose of 4 mg/m2 every 2 weeks. Five patients had not been splenectomized, and one had failed to respond to interferon-alpha. Complete remission, as defined by absence of hairy cells in the bone marrow and normalization of the peripheral blood and regression of splenomegaly, was obtained in 11 of 12 patients (92%). These patients have remained in unmaintained remission for 1+ to 13 months with an average of 7.5 months. Two of these patients had a bone marrow relapse at 8 and 12 months, respectively. During treatment the monocytopenia corrected, and, after complete remission was obtained, marrow was aspirable. Toxicity was mild and reversible. There were no significant infections associated with this treatment. It was of interest that we could treat two patients with creatinine clearance of 50 and 60 ml/min using lower doses (and 2-3 mg/m2) than our conventional therapy of 4 mg/m2 every 2 weeks. They obtained a complete remission after 6 and 10 treatments, respectively. Low-dose deoxycoformycin has proven to be an excellent treatment for hairy cell leukemia.
Leukemia 1987 Apr
PMID:Treatment of hairy cell leukemia: the Ohio State University experience with deoxycoformycin. 349 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>